Shankar Sridhar, vanSonnenberg Eric, Desai Jayesh, Dipiro Pamela J, Van Den Abbeele Annick, Demetri George D
Department of Radiology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass, USA.
Radiology. 2005 Jun;235(3):892-8. doi: 10.1148/radiol.2353040332. Epub 2005 Apr 15.
To investigate a new pattern of tumor recurrence observed at imaging in patients with metastatic gastrointestinal stromal tumor (GIST) after initial partial response to imatinib mesylate.
Ninety-two patients with metastatic GIST who underwent treatment in a clinical trial with oral imatinib mesylate were followed up for 29 months. An institutional review board-approved protocol was used. The study complied with the Health Insurance Portability and Accountability Act, and written informed consent was obtained from all patients. Images of the chest, abdomen, and pelvis, acquired with computed tomography (CT), positron emission tomography (PET), and, in some cases, magnetic resonance imaging, were evaluated for treatment response and disease recurrence. Thirty-nine patients (29 men, 10 women; age range, 18-84 years; mean, 49.2 years) had recurrent disease after an initial variable period of response (range, 2-24 months; median, 14.4 months). Initial response was determined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumor, and decreased attenuation at CT. Images were evaluated for disease recurrence by two experienced radiologists who were blinded to each other's interpretation but not to clinical details. Final reading was performed by consensus.
A nodule within a mass was seen in 21 of 39 patients (in intrahepatic tumor [n = 8], extrahepatic tumor [n = 10], or both intra- and extrahepatic tumors [n = 3]) and was the first sign of disease progression in 17 of 21 patients. Other patterns of recurrence included new site of disease (n = 7), regrowth of preexistent lesion (n = 20), and mixed (more than one) pattern (n = 9). Disease progression was verified at needle biopsy (n = 16), follow-up imaging (n = 14), and/or surgical resection (n = 9).
A nodule within a mass is an important sign of recurrent GIST, but measurements of overall tumor size may not enable detection of such nodules.
研究转移性胃肠道间质瘤(GIST)患者在对甲磺酸伊马替尼初始部分缓解后影像学检查中观察到的肿瘤复发新模式。
92例接受口服甲磺酸伊马替尼临床试验治疗的转移性GIST患者接受了29个月的随访。采用了经机构审查委员会批准的方案。该研究符合《健康保险流通与责任法案》,并获得了所有患者的书面知情同意。对通过计算机断层扫描(CT)、正电子发射断层扫描(PET)以及在某些情况下通过磁共振成像获得的胸部、腹部和骨盆图像进行治疗反应和疾病复发评估。39例患者(29例男性,10例女性;年龄范围18 - 84岁;平均49.2岁)在初始不同反应期(范围2 - 24个月;中位数14.4个月)后出现疾病复发。根据PET上氟-18氟脱氧葡萄糖摄取减少、肿瘤缩小以及CT上衰减降低的表现确定初始反应。由两名经验丰富的放射科医生对图像进行疾病复发评估,他们彼此不知道对方的解读,但了解临床细节。最终解读通过共识达成。
39例患者中有21例(肝内肿瘤8例、肝外肿瘤10例或肝内和肝外肿瘤均有3例)在肿块内可见结节,其中17例患者该结节是疾病进展的首个迹象。其他复发模式包括新发病灶(7例)、原有病灶再生长(20例)以及混合(不止一种)模式(9例)。通过针吸活检(16例)、随访影像学检查(14例)和/或手术切除(9例)证实疾病进展。
肿块内结节是复发性GIST的重要征象,但测量肿瘤总体大小可能无法检测到此类结节。